URGN vs UTHR Stock Comparison

UTHR currently leads URGN in this stock comparison, with AIQ scores of 76 vs 53. The clearest difference is risk resilience.

Market data as of Nov 15, 2026 market close· AIQ score gap 23 points
URGN
Healthcare
vs
UTHR
Healthcare
URGN
UroGen Pharma Ltd.
Price
$26.18
Day move
-0.8%
AIQ Score
53/100
Best edge
Balanced
Sector
Healthcare
UTHR
United Therapeutics Corporation
Leads
Price
$591
Day move
-0.36%
AIQ Score
76/100
Best edge
Risk Resilience
Sector
Healthcare

What is the main difference between URGN and UTHR?

UTHR leads the current stock comparison as United Therapeutics Corporation, with the clearest separation coming from risk resilience and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

UroGen Pharma Ltd. vs United Therapeutics Corporation

Data as of Nov 15, 2026· market close· Healthcare· Coverage 64/66 fields· High confidence
AIQ VerdictCompetitiveAIQ Comparison Conviction 8/10

UTHR leads

UTHR leads by 23 AIQ points, primarily on Risk Resilience and Momentum, and the lead has widened from 8 points over 30 sessions. Wall Street currently favors URGN on target upside.

Competitive: 4 of 6 evidence groups support UTHR, its lead is widening, and its current signal state is conflicted.

Evidence agreement: 4 of 6Comparison trend: Strengthening
URGN

UroGen Pharma Ltd.

AIQ Score
53/100
AIQ Edge Score
5/10
UTHR

United Therapeutics Corporation

Leads
AIQ Score
76/100
AIQ Edge Score
10/10

The Algovestiq AIQ Score currently favors UTHR over URGN, 76 versus 53 as of Nov 15, 2026. UTHR's advantage is driven primarily by stronger risk resilience and momentum. UTHR also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors URGN. 4 of 6 covered evidence groups favor UTHR today, and the comparison is rated Competitive on stability: the leader is throwing conflicting signals. UTHR lead: Strengthening — the AIQ differential moved from 8 to 23 points over 30 sessions. UTHR leads on all four AIQ factor dimensions. Value is itself one of those four, so a sweep is not explained by valuation alone — it deserves additional scrutiny for unmodeled catalysts, expectations or event risk.

Compare UroGen Pharma Ltd. and United Therapeutics Corporation across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

URGN
+100.5%
UTHR
+196.5%

Price return comparison

Growth of $10,000, price only

URGN $20,046 · UTHR $29,646

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare URGN and UTHR against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

URGN advantage
0
UTHR advantage
  • Risk Resilience40 vs 83
    UTHR +43
  • Momentum40 vs 68
    UTHR +28
  • Value64 vs 78
    UTHR +14
  • Quality68 vs 81
    UTHR +13

4 of 6 evidence groups favor UTHR. UTHR’s edge is concentrated in risk resilience and momentum.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

URGN0 AIQ

Largest factor move: Value +2, not enough on its own to move the overall score.

No signal started or stopped since the prior session; its 5 active signals are unchanged.

UTHR-1 AIQ

Largest factor move: Momentum -1

New signals

  • MACD Histogram Expanding Bearish — bearish, momentum, short horizon

UTHR's lead narrowed by 1 AIQ point in the latest session.

Deeper signal detail for each name lives on its own signals page — URGN and UTHR both carry a full feed there.

The central trade-off

UTHR (United Therapeutics Corporation): the stronger current systematic profile, led by risk resilience and momentum.

URGN (UroGen Pharma Ltd.): the counter-case, on fundamentals, analyst expectations — but at materially higher volatility, 79.4% against 34.8%.

The AIQ Score and Wall Street therefore point in different directions on this pair.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

UTHR

UTHR on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

URGN

URGN on combined revenue and EPS growth.

Value

UTHR

UTHR on the peer-relative Value factor, by 14 points.

Momentum

UTHR

UTHR on the Momentum factor, by 28 points.

Lower downside

UTHR

UTHR on Risk Resilience, by 43 points.

Analyst upside

URGN

URGN on implied upside to the consensus price target.

AIQ vs Wall Street

The model and the Street disagree here: AIQ favors UTHR, analyst targets favor URGN. That disagreement is the most useful thing on this page.

MeasureURGNUTHRNote
Implied upside to target+121.5%+16.3%URGN has more room
Target dispersion+6.9%+70.1%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering816Higher coverage generally improves confidence

The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

4 of 6 covered evidence groups favor UTHR. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreUTHR53 vs 76
FundamentalsURGNon balancerevenue growth 22.8% vs 6.3%; EPS growth 89.3% vs -22.5%; TTM ROE 1.2% vs 4.1%; gross margin 91.4% vs 86.3%; operating margin -12.4% vs 41.5% — URGN takes 3 of 5 decided legs, not all of them
ValuationUTHRValue 64 vs 78
TechnicalsUTHRPrice vs 50-day -29.2% vs 9%; vs 200-day -17.4% vs 10%
Risk ResilienceUTHRRisk Resilience 40 vs 83
Analyst expectationsURGNTarget upside 121.5% vs 16.3%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of URGN and UTHR and are excluded from the count.

AIQ Decision Stability

Competitive

The two are close enough that your objective, not the score, should decide.

  • The AIQ gap is wide at 23 points. (supports the conclusion holding)
  • The leader's advantage has been widening. (supports the conclusion holding)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)
  • Analyst targets on the leader are widely dispersed. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on UTHR.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

UTHR lead: Strengthening — the AIQ differential moved from 8 to 23 points over 30 sessions.

May 27URGN leads above the line · UTHR leads belowNov 13
Today
UTHR +23
53 vs 76
7 sessions ago
UTHR +19
57 vs 76
30 sessions ago
UTHR +8
63 vs 71
90 sessions ago
Level
70 vs 70

The lead changed hands 2 times in this window, most recently on Aug 27 when UTHR moved ahead of URGN.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

URGNConflicted

2 bullish / 1 bearish / 2 neutral, conflicted

Only URGN

  • ATR Expansion - Breakout Mode — neutral, volatility, short horizon (7.71%)
  • Keltner Channel Breakdown — bearish, volatility, short horizon
  • RSI Oversold — bullish, momentum, short horizon
UTHRConflicted

5 bullish / 2 bearish / 1 neutral, conflicted

Only UTHR

  • 52-Week High Proximity — bullish, risk_regime, long horizon (2.5%)
  • Drawdown Recovery Signal — bullish, risk_regime, long horizon (-10.6%)
  • EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
  • MACD Histogram Expanding Bearish — bearish, momentum, short horizon
  • RSI Bearish Divergence — bearish, momentum, medium horizon
  • Uptrend Structure Active — bullish, trend, long horizon

Both carry 2 more signals that do not separate them: Golden Cross Active, ADX Trend Strengthening.

UTHR leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

URGNNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -0.8%, AIQ 0 points).

UTHRConfirmed weakness

Price and the AIQ Score both moved down over the latest session (price -0.36%, AIQ -1 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1URGN closes the Risk Resilience gap — currently 43 points behind, the largest single contributor to UTHR's edge.
  2. 2URGN's Keltner Channel Breakdown resolves — a bearish volatility rule currently active against it.
  3. 3UTHR's conflicting signal state resolves bearish — it currently carries 5 bullish and 2 bearish rules at once.
  4. 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

URGN leads on balance
MetricURGNUTHR
Revenue growth (YoY)22.8%6.3%
EPS growth (YoY)89.3%-22.5%
Gross margin91.4%86.3%
Operating margin-12.4%41.5%
Return on equity (TTM)1.2%4.1%
Debt to equity-1.570

Performance

UTHR leads 5 of 6 windows
MetricURGNUTHR
1 week (5 sessions)5.8%5.2%
1 month (20 sessions)-24.2%10.9%
3 months (63 sessions)-46.7%16.3%
6 months (126 sessions)-9%4%
Year to date11.8%21.3%
1 year (252 sessions)4.1%28.1%

Technicals

UTHR has the stronger structure
MetricURGNUTHR
RSI (14)28.758
ADX (14)45.120.9
Price vs 50-day-29.2%9%
Price vs 200-day-17.4%10%
Volatility (1M, annualized)79.4%34.8%

Risk

UTHR is the more resilient
MetricURGNUTHR
Beta1.330.42
Sharpe ratio0.390.76
Sortino ratio0.561.4
Max drawdown-50.8%-20.9%
Current drawdown-47.9%-2.8%
Annualized volatility61.9%35%
Value at risk (95%)-5.5%-2.4%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, URGN or UTHR?

On the Algovestiq AIQ Score, UTHR is the stronger of the two as of Nov 15, 2026, scoring 76 against URGN's 53. The edge comes from risk resilience and momentum. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is URGN or UTHR the better buy right now?

UTHR carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Competitive — 4 of 6 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.

Why does the AIQ Score favor UTHR over URGN?

The composite weights Quality, Value, Momentum and Risk Resilience. UTHR leads Risk Resilience by 43 points; UTHR leads Momentum by 28 points; UTHR leads Value by 14 points. UTHR leads on all four AIQ factor dimensions. Value is itself one of those four, so the sweep is not explained by URGN simply being cheaper — it warrants extra scrutiny for unmodeled catalysts, forward expectations or event risk the factors do not capture.

Which has more analyst upside, URGN or UTHR?

Analyst price targets imply +121.5% upside for URGN and +16.3% for UTHR, so the Street currently favors URGN. That points the opposite way to the AIQ Score, which favors UTHR. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, URGN or UTHR?

UTHR is the better-valued of the two on the peer-relative Value factor. UTHR on the peer-relative Value factor, by 14 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, URGN or UTHR?

URGN on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, URGN or UTHR?

UTHR on the Momentum factor, by 28 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, URGN or UTHR?

UTHR is the more resilient of the two, so the other name carries the higher downside risk. UTHR on Risk Resilience, by 43 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is URGN more profitable than UTHR?

The profitability evidence is mixed: gross margin 91.4% vs 86.3%; operating margin -12.4% vs 41.5%; ttm roe 1.2% vs 4.1%. URGN leads on one measure and UTHR on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.

Is UTHR's lead over URGN getting stronger or weaker?

UTHR lead: Strengthening — the AIQ differential moved from 8 to 23 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands 2 times in that window, most recently on 2026-08-27, when UTHR moved ahead of URGN.

What would change the URGN vs UTHR verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: URGN closes the Risk Resilience gap — currently 43 points behind, the largest single contributor to UTHR's edge; URGN's Keltner Channel Breakdown resolves — a bearish volatility rule currently active against it; UTHR's conflicting signal state resolves bearish — it currently carries 5 bullish and 2 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

What do the current signals say about URGN and UTHR?

URGN: 2 bullish / 1 bearish / 2 neutral, conflicted. UTHR: 5 bullish / 2 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on URGN is Golden Cross Active (bullish, long horizon). On UTHR it is Golden Cross Active (bullish, long horizon).

Compare URGN and UTHR with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.